Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 17/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16165005 | 1.00 | S1PR3 (0.41) | S1PR3S1PR1S1PR4S1PR2JAK2 | |
| SCHEMBL16207774 | 0.91 | JAK3 (0.43) | S1PR3S1PR1S1PR4S1PR2JAK2 | |
| SCHEMBL16760789 | 0.91 | JAK3 (0.43) | S1PR3S1PR1S1PR4S1PR2JAK2 | |
| SCHEMBL16207729 | 0.90 | CYP1A2 (0.39) | S1PR3S1PR1S1PR4JAK2JAK3 | |
| SCHEMBL16207730 | 0.90 | CYP1A2 (0.39) | S1PR3S1PR1S1PR4JAK2JAK3 | |
| SCHEMBL16164554 | 0.88 | JAK2 (0.35) | S1PR3S1PR1S1PR4JAK2JAK3 | |
| SCHEMBL16164556 | 0.88 | JAK2 (0.35) | S1PR3S1PR1S1PR4JAK2JAK3 | |
| SCHEMBL16207782 | 0.88 | KHK (0.37) | S1PR3S1PR1S1PR4S1PR2JAK2 | |
| SCHEMBL16207787 | 0.87 | S1PR3 (0.42) | S1PR3S1PR1S1PR4S1PR2JAK2 | |
| SCHEMBL16760783 | 0.87 | S1PR3 (0.42) | S1PR3S1PR1S1PR4S1PR2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051310-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20140309225-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309225-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, BTK, NOX4 | S1PR3 144/4885S1PR1 119/4885S1PR4 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.